1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > EpiCast Report: Migraine - Epidemiology Forecast to 2023

EpiCast Report: Migraine - Epidemiology Forecast to 2023

  • February 2014
  • -
  • GlobalData
  • -
  • 44 pages

EpiCast Report: Migraine - Epidemiology Forecast to 2023

Summary

Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following symptoms: nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal and Lipton, 2006). Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization (WHO) (Leonardi et al., 2005; Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine as the first among the neurological disorders (Leonardi and Raggi, 2013).

In 2023, GlobalData epidemiologists forecast that the total prevalent cases of migraine in the 7MM remained almost the same, with 75.83 million total prevalent cases in 2013 and 76.38 million total prevalent cases, with an annual growth rate (AGR) of 0.07% in the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of migraine, with 29.61 million total prevalent cases in 2013 and 31.13 million total prevalent cases in 2023.

GlobalData epidemiologists obtained total prevalence data for migraine from peer-reviewed journals and population-based studies in the respective markets and used consistent methodology to ensure comparability of results. Furthermore, GlobalData epidemiologists made a meaningful assumption that the age- and sex-specific total prevalence of migraine in the 7MM would remain constant throughout the forecast period because epidemiologic literature suggests relatively stable trends in the prevalence of migraine worldwide, thereby providing a realistic and meaningful forecast for the age- and sex-specific total prevalent cases of migraine in the 7MM.

Scope

- The Migraine EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of migraine in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by age (beginning at 18 years and ending at 80 years and older), sex, and the number of total prevalent cases of migraine with aura and without aura in these markets.
- The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global migraine market.
- Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for migraine therapeutics in each of the markets covered.
- Identify the number of migraine cases with aura and without aura.

Table Of Contents

EpiCast Report: Migraine - Epidemiology Forecast to 2023
1 Table of Contents

2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.2.1 Female sex and family history are interrelated risk factors of migraine 9
3.2.2 People with migraine also suffer from several comorbidities 10
3.3 Global Trends 11
3.3.1 US 12
3.3.2 5EU 13
3.3.3 Japan 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 17
3.4.2 Sources Not Used 20
3.4.3 Forecast Assumptions and Methods 20
3.5 Epidemiological Forecast for Migraine (2013-2023) 25
3.5.1 Total Prevalent Cases of Migraine 25
3.5.2 Age-Specific Total Prevalent Cases of Migraine 26
3.5.3 Sex-Specific Total Prevalent Cases of Migraine 28
3.5.4 Age-Standardized Total Prevalence of Migraine 30
3.5.5 Total Prevalent Cases of Migraine with Aura and Migraine without Aura 32
3.6 Discussion 33
3.6.1 Conclusions on Epidemiological Trends 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 35
4 Appendix 36
4.1 Bibliography 36
4.2 About the Authors 40
4.2.1 Epidemiologists 40
4.2.2 Reviewers 40
4.2.3 Global Director of Epidemiology and Health Policy 41
4.2.4 Global Head of Healthcare 42
4.3 About GlobalData 43
4.4 About EpiCast 43
4.5 Disclaimer 43

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Migraine 9
Table 2: Prevalence of the Most Frequent Comorbidities in People with and without Migraine, Ages ?18 Years, Both Sexes 11
Table 3: One-Year Total Prevalence (%) of Migraine in the 5EU 14
Table 4: Lifetime Total Prevalence (%) of Migraine in the 3EU 14
Table 5: Criteria Proposed by the Second Edition of the International Classification of Headache Disorders (ICHD-2) 15
Table 6: Epidemiological Sources of Total Prevalence Data Used in the Analysis for Migraine and its Subtypes (Migraine with Aura and Migraine without Aura) 16
Table 7: 7MM, Total Prevalent Cases of Migraine, Ages ?18 Years, Both Sexes, N, 2013-2023 25
Table 8: 7MM, Total Prevalent Cases of Migraine, by Age, Both Sexes, N, (Row %), 2013 27
Table 9: 7MM, Total Prevalent Cases of Migraine, by Sex, Ages ?18 years, N (Row %), 2013 29
Table 10: 7MM, Total Prevalent Cases of Migraine with Aura and Migraine without Aura, Ages ?18 Years, Both Sexes, N, Row (%), 2013 32

1.2 List of Figures

Figure 1: 7MM, Total Prevalent Cases of Migraine, Ages ?18 Years, Both Sexes, N, 2013-2023 26
Figure 2: 7MM, Total Prevalent Cases of Migraine, by Age, Both Sexes, N, 2013 28
Figure 3: 7MM, Total Prevalent Cases of Migraine, by Sex, Ages ?18 Years, N, 2013 30
Figure 4: 7MM, Age-Standardized Total Prevalence of Migraine, Ages ?18 Years, 2013 31
Figure 5: 7MM, Total Prevalent Cases of Migraine with Aura and Migraine without Aura, Ages ?18 Years, Both Sexes, N, Row (%), 2013 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dysmenorrhea  - Market Insights, Epidemiology and Market Forecast-2023

Dysmenorrhea  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dysmenorrhea - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Migraine  - Market Insights, Epidemiology and Market Forecast-2023

Migraine  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Migraine - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

North America Pet Nutraceuticals Market

North America Pet Nutraceuticals Market

  • $ 3850
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The total North American Pet Nutraceuticals market is valued at over $1528.4 million in 2015 and is projected to reach over $XX million by 2020 growing at a CAGR of XX% between the years 2015 and 2020. ...


Download Unlimited Documents from Trusted Public Sources

The future of the Pain Relief Industry in the UK

  • February 2017
    5 pages
  • Pain Relief  

  • United Kingdom  

View report >

Pain Relief Industry in the US

  • January 2017
    7 pages
  • Pain Relief  

  • United States  

View report >

Pain Relief Industry in the US

  • January 2017
    20 pages
  • Pain Relief  

    Therapy  

  • United States  

View report >

Otc Markets In China

3 months ago

Related Market Segments :

Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.